Health IT Analytics February 16, 2018
Roche Pharmaceuticals will spend $1.9 billion to buy the cancer analytics, EHR, and precision medicine assets of Flatiron Health.
Swiss pharmaceutical giant Roche will purchase Flatiron Health’s cancer analytics assets for $1.9 billion in an effort to enhance the drug development process and further the progress of precision medicine.
Flatiron Health, backed by Google parent company Alphabet Inc., also offers an electronic health record (EHR) tailored to the needs of oncologists while focusing on curating and developing real-world evidence for cancer research and the application of personalized therapies.
Roche already owned more than 12 percent of the company, but will acquire all shares in the massive new purchase.
Dig Deeper
Today's Sponsors
Today's Sponsor